Condition: Myopia · Sponsor: Laboratoires Thea
Axial myopia is a type of nearsightedness that happens when the eye is too long from front to back. This causes distant vision to be blurry. Axial myopia tends to start during childhood and worsens over time (as the eyes continue to grow longer). This can lead to serious eye-related conditions later in life. The aim of T10430 treatment is to stop or slow this progression during childhood and therefore, prevent more serious complications. Animal studies using drugs with a similar mechanism of action as T10430 have demonstrated positive safety results. This study aims to better understand the safety and potential effectiveness of T10430 in children with axial myopia.
This description comes directly from the study's public registry record.
Corentin LE CAMUS · +33473981436 · corentin.lecamus@theapharma.com
Always discuss trial participation with your own doctor first.
| Abdali Hospital | Amman, Jordan | Not Yet Recruiting |
| Istiklal Hospital | Amman, Jordan | Not Yet Recruiting |
| Jordan University Hospital | Amman, Jordan | Not Yet Recruiting |
| Irbid Specialty Hospital | Irbid, Jordan | Not Yet Recruiting |
| Pharmaceutical research center at Jordan University of Science and Technology | Irbid, Jordan | Not Yet Recruiting |
| IATROS INTERNATIONAL PTY Ltd | Brandwag, South Africa | Recruiting |
| Pretoria Eye Institute Research Foundation | Pretoria, South Africa | Recruiting |
| Hôpital Universitaire Tahar Sfar Mahdia | Mahdia, Tunisia | Not Yet Recruiting |
| Hôpital Farhat-Hached | Sousse, Tunisia | Not Yet Recruiting |
| Hôpital Charles Nicolle | Tunis, Tunisia | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07522242